StaffNovember 5, 2018
Denver, Colorado, November 5, 2018 /AxisWire/ Nexien BioPharma Inc. (OTC QB: NXEN) (“Nexien” or the “Company”) announced that it was initiating an investigation into the use of cannabinoid-based formulations for the treatment of patients suffering from Myotonic Dystrophy (DM) and Myotonia. Munich-based Dr. Benedikt Schoser, who joined Nexien as a scientific advisor in July, and […]
